Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SATIVEX AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL

Next Previous
Search
Trial Profile

SATIVEX AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Muscle spasticity
  • Focus Therapeutic Use
  • Acronyms SAVANT
  • Sponsors Almirall Hermal GmbH

    • Most Recent Events

    • 09 Nov 2022 Results assessing Cost-Utility of Nabiximols for the Management of Spasticity Due to Multiple Sclerosis in Switzerland presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 26 Apr 2022 Results of two studies (SAVANT and GWSP0604) assessing treatment outcomes for people with multiple sclerosis (PwMS) spasticity taking nabiximols with or without concomitant antispasticity medications (ASMs), such as baclofen, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
    • 26 Apr 2022 Results assessing treatment effect of nabiximols during each week of the double-blind, placebo-controlled portion of GWSP0604 and SAVANT using an equivalent statistical model, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top